Organon & CO Form 4 insider transactions

Aaron Falcione, Chief Human Resources Officer of Organon & Co., reports the vesting of Restricted Stock Units (RSUs) and the grant of stock options.

Executive VP of Corporate Development at Organon & Co., Daniel Karp, reports the acquisition and disposal of common stock and derivative securities due to stock option grants and restricted stock unit (RSU) vesting on March 31, 2025.

Rachel A. Stahler, Chief Information Officer of Organon & Co., reports the grant of stock options and vesting of restricted stock units (RSUs) on March 31, 2025, resulting in changes to her beneficial ownership of the company's common stock.

Chief Financial Officer of Organon & Co., Matthew Walsh, reports the vesting of Restricted Stock Units (RSUs) and the grant of stock options.

Head of R&D & CMO, Juan Camilo Arjona Ferreira, reports transactions involving Organon & Co. stock, including the vesting of restricted stock units and the grant of stock options and additional RSUs.

Kirke Weaver, General Counsel & Corporate Secretary of Organon & Co., reports transactions involving common stock and derivative securities, including stock options and restricted stock units, on March 31, 2025.

Kathryn DiMarco, Corporate Controller of Organon & Co., reports transactions involving common stock and restricted stock units.

Vittorio Nisita, Head of Global Business Services at Organon & Co., reports the vesting of restricted stock units (RSUs) and the grant of stock options.

Joseph T. Morrissey, Jr., Head of Manufacturing at Organon & Co., reports the vesting of Restricted Stock Units (RSUs) and the grant of stock options.

CEO Kevin Ali reports the vesting of restricted stock units (RSUs) and the grant of stock options in Organon & Co.

Chief Financial Officer Matthew M. Walsh reports acquisition and disposal of Organon & Co. common stock related to performance share units.

Chief Information Officer Rachel A. Stahler reports acquisition and disposal of Organon & Co. common stock related to performance share units and dividend reinvestments.

Vittorio Nisita, Head of Global Business Services at Organon & Co., reports transactions involving Organon common stock, including acquisitions from performance share unit (PSU) vesting and dividend equivalents, as well as dispositions to cover tax obligations.

Chief Human Resources Officer Aaron Falcione reports acquisition and disposal of Organon & Co. common stock related to performance share units and dividend reinvestments.

Joseph T. Morrissey Jr., Head of Manufacturing at Organon & Co., reports acquisition and disposal of company stock related to performance share units and dividend reinvestments.

Organon CEO Kevin Ali reports acquisition and disposal of company stock related to performance share units (PSUs) and dividend reinvestments.

Juan Camilo Arjona Ferreira, Head of R&D & CMO at Organon & Co., reports transactions involving common stock and restricted stock units.

CEO Kevin Ali reports acquisition of shares through performance share units and disposal of shares to cover tax obligations.

Rachel Stahler, Chief Information Officer of Organon & Co., reports the vesting of performance share units and subsequent tax withholding.

Vittorio Nisita, Head of Global Business Services at Organon & Co., reports acquisition and disposal of company stock.

Chief Human Resources Officer Aaron Falcione reports acquisition of shares through performance share unit vesting and disposition of shares to cover tax obligations.

Chief Financial Officer of Organon & Co., Matthew Walsh, reports acquisition of shares through performance share units and disposal of shares to cover tax obligations.

Kathryn DiMarco, Corporate Controller of Organon & Co., reports acquisition and disposal of common stock following performance share unit vesting.

Joseph T. Morrissey, Jr., Head of Manufacturing at Organon & Co., reports acquisition of shares through performance share units and subsequent disposal to cover tax obligations.

Chief Commercial Officer Susanne Fiedler reports acquisition of 3,594 shares of Organon & Co. common stock and disposition of 1,145 shares to cover tax obligations.

Juan Camilo Arjona Ferreira, Head of R&D & CMO at Organon & Co., exercised restricted stock units and sold a portion of the acquired shares on August 11, 2024.

Director Cynthia M. Patton reports acquiring phantom stock units equivalent to 9,638.554 shares of Organon & Co. common stock at a price of $20.75 per unit.

Director Shalini Sharp reports acquiring phantom stock units in Organon & Co. through the company's Non-Employee Director Savings Plan.

Director Alan Ezekowitz reports acquiring phantom stock units in Organon & Co. through a non-employee director savings plan.

Director Helene D. Gayle reports acquisition of phantom stock units in Organon & Co. through a non-employee director savings plan.